NeuroTargets.co.uk
Title
Neurotargets - Breakthrough Treatments
Description
Founded in 1999 by ANGLE plc to commercialise the research of Professor David Wynick at Bristol University, NeuroTargets was founded as a genomics-based company. It has been providing specialised services to the pharmaceutical industry for over five years. It is best known for its work in identifying drug targets for development in collaboration with other organisations including MSD and BioFocus.
Successful discovery and validation of drug targets has provided the starting point for the next stage in the Company's development. NeuroTargets' and its business strategy is now focused on the development of novel therapeutic products with innovative mechanisms of action, in areas of high unmet medical need related to nerve injury.
Additional Information
- Alzheimer's Disease Research
- Amputation
- Biotechnology And Pharmaceuticals
- Business
- Chronic
- Diabetes
- Diabetic Neuropathy
- Functional Genomics
- Galanin
- Gene Discovery
- Gene Libraries
- Inflammatory
- Neuropathic Pain
- Neuroprotection
- Pain Management
- Pain Relief
- Peripheral Neuropathy
- Phantom Limb Pain
- Pharmaceuticals
- Regeneration
- Research And Development
- Sensory Neurons
- Stroke
- Target Validation
- Biotechnology and Pharmaceuticals
- Research and Development